<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">ATP P2X3 Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>ATP P2X3 Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
ATP P2X3 Receptor Neurons represent a specialized population of sensory neurons that express the P2X3 purinergic receptor, an ATP-gated ion channel that plays critical roles in detecting ATP release associated with tissue damage, inflammation, and neural activity. The P2X3 receptor is a member of the P2X receptor family, which comprises seven ligand-gated ion channel subunits (P2X1-P2X7) that form homomeric and heteromeric trimeric channels in response to extracellular ATP. P2X3 receptors are uniquely expressed in a subset of sensory neurons, particularly those involved in nociception (pain detection), visceral sensation, and chemosensation. These receptor neurons are primarily located in peripheral sensory ganglia including the dorsal root ganglia (DRG), trigeminal ganglia, and nodose ganglia, as well as in certain central nervous system regions involved in sensory processing. The role of P2X3 receptor neurons extends beyond acute pain sensing to include contributions to chronic pain states, neuroinflammation, and possibly neurodegenerative disease processes, making them important therapeutic targets. [@p burner][@p ryan]
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">ATP P2X3 Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>ATP P2X3 Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
ATP P2X3 Receptor Neurons represent a specialized population of sensory neurons that express the P2X3 purinergic receptor, an ATP-gated ion channel that plays critical roles in detecting ATP release associated with tissue damage, inflammation, and neural activity. The P2X3 receptor is a member of the P2X receptor family, which comprises seven ligand-gated ion channel subunits (P2X1-P2X7) that form homomeric and heteromeric trimeric channels in response to extracellular ATP. P2X3 receptors are uniquely expressed in a subset of sensory neurons, particularly those involved in nociception (pain detection), visceral sensation, and chemosensation. These receptor neurons are primarily located in peripheral sensory ganglia including the dorsal root ganglia (DRG), trigeminal ganglia, and nodose ganglia, as well as in certain central nervous system regions involved in sensory processing. The role of P2X3 receptor neurons extends beyond acute pain sensing to include contributions to chronic pain states, neuroinflammation, and possibly neurodegenerative disease processes, making them important therapeutic targets. [@p burner][@p ryan]
The P2X3 receptor is encoded by the P2RX3 gene located on chromosome 7q36.1 in humans. Like other P2X subunits, P2X3 contains two transmembrane domains, an extracellular loop containing the ATP-binding site, and intracellular N- and C-termini. Upon ATP binding, the P2X3 receptor undergoes a conformational change that opens a central channel pore permeable to sodium, potassium, and calcium ions. The channel exhibits rapid desensitization kinetics, with currents decaying rapidly during continued ATP application, a property that makes it well-suited for detecting transient ATP release events. P2X3 receptors can form functional homomeric channels or heteromeric channels with other P2X subunits, particularly P2X2, creating receptors with distinct pharmacological properties. The desensitization kinetics and single-channel properties of P2X3 receptors make them uniquely suited for detecting patterns of ATP release associated with tissue injury and inflammation. [@p ryan][@p fowler]
P2X3 receptors are activated by ATP and its analogs with varying potency. α,β-Methylene ATP (α,β-meATP) is a potent agonist that produces rapid, desensitizing responses at P2X3 receptors. The pharmacological profile of P2X3 receptors distinguishes them from other P2X subtypes, enabling development of selective antagonists. Several P2X3 receptor antagonists have been developed and evaluated in clinical trials for chronic pain, overactive bladder, and chronic cough. Gefapixant (AF-219/MK-7264) is a P2X3 receptor antagonist that showed efficacy in reducing chronic cough frequency in clinical trials, representing the first P2X3-targeted drug to achieve regulatory approval. Other P2X3 antagonists in development include BLU-5937 and S-600918, which are being evaluated for chronic pain and other indications. The success of P2X3 antagonists in clinical settings validates the receptor as a viable therapeutic target. [@p bjorn][@p xu]
P2X3 receptors are highly expressed in small-diameter sensory neurons in dorsal root ganglia (DRG), where they are concentrated in a subset of nociceptive neurons that also express the nerve growth factor receptor TrkA and the capsaicin receptor TRPV1. These neurons are primarily unmyelinated C-fibers and thinly myelinated Aδ-fibers that convey pain and temperature information to the spinal cord. Within DRG neurons, P2X3 receptors are localized to both the cell body and central and peripheral nerve terminals, where they detect ATP released from damaged cells, inflammatory cells, and adjacent nerve terminals. The selective expression of P2X3 in pain-sensing neurons makes it an attractive target for developing analgesics with reduced side effects compared to traditional opioids. [@p ryan][@p wu]
P2X3 receptors are abundantly expressed in the trigeminal ganglion, where they contribute to craniofacial pain perception including migraine and temporomandibular disorder pain. Within the trigeminal nucleus caudalis (the spinal nucleus of the trigeminal nerve), P2X3 receptors are expressed on central terminals of primary sensory neurons and on second-order neurons that receive input from intracranial and extracranial structures. The trigeminovascular system, which mediates migraine pain through activation of trigeminal afferents innervating intracranial blood vessels, expresses P2X3 receptors that contribute to pain signaling. P2X3 receptor antagonists have shown efficacy in preclinical models of migraine, suggesting potential therapeutic applications in this prevalent condition. [@p martinez]
P2X3 receptors are expressed in sensory neurons innervating visceral organs including the urinary bladder, gastrointestinal tract, and lungs. In the bladder, P2X3 receptors on afferent fibers in the bladder wall detect bladder distension and contribute to normal urination reflexes as well as bladder overactivity in pathological conditions. In the gastrointestinal tract, P2X3 receptors mediate visceral pain and contribute to functional disorders such as irritable bowel syndrome. In the lungs, P2X3 receptors detect ATP released during respiratory distress and contribute to the sensation of breathlessness. These visceral sensory functions explain the efficacy of P2X3 antagonists in treating overactive bladder and chronic cough. [@p li][@p xu]
P2X3 receptor neurons are crucial for detecting ATP released during tissue damage and initiating acute pain signals. When tissues are injured, ATP is released from damaged cells, activated platelets, and immune cells, creating a "danger signal" that activates P2X3 receptors on nearby nociceptors. This ATP-P2X3 signaling is particularly important for detecting deep tissue injury and inflammatory pain, where ATP release is prolonged compared to brief mechanical stimuli. P2X3 receptors contribute to both the detection of noxious stimuli and the sensitization of nociceptors that amplifies pain signaling. The rapid desensitization of P2X3 receptors may help prevent overactivation during sustained ATP release, though this property can also limit the receptor's effectiveness in chronic conditions. [@p ryan][@p wu]
In chronic pain conditions including neuropathic pain, inflammatory pain, and cancer pain, P2X3 receptor expression and function are often upregulated, contributing to pain hypersensitivity. Following nerve injury, P2X3 receptor expression increases in DRG neurons, and this upregulation is associated with enhanced ATP sensitivity and increased pain behaviors in animal models. P2X3 receptor antagonists reduce pain behaviors in models of neuropathic pain, inflammatory pain, and cancer pain, validating the receptor as a therapeutic target. Additionally, P2X3 receptors on central nervous system neurons may contribute to spinal cord pain processing and central sensitization. The clinical success of gefapixant in chronic cough suggests that P2X3 antagonists may also be effective for chronic pain conditions, though clinical trials in chronic pain have shown mixed results. [@p bjorn][@p xu]
P2X3 receptors are expressed not only on neurons but also on glial cells including astrocytes and microglia, where they contribute to neuroinflammatory processes. Activation of P2X3 receptors on glial cells triggers release of pro-inflammatory cytokines and other mediators that can sensitize adjacent neurons and promote pain transmission. In neurodegenerative conditions, neuroinflammation is a major contributor to disease progression, and P2X3 receptors may participate in this process. The bidirectional relationship between P2X3-mediated neuroinflammation and neuronal dysfunction creates a feedforward loop that could accelerate neurodegeneration in conditions like Alzheimer's disease and Parkinson's disease. Understanding how P2X3 receptors contribute to neuroinflammation may reveal new therapeutic strategies for these conditions. [@p chen]
Emerging evidence suggests that P2X3 receptors may contribute to the pathogenesis of certain neurodegenerative diseases, though this area of research is less developed than the pain field. In Parkinson's disease models, P2X3 receptor expression is altered in brain regions involved in motor control, and P2X3 antagonists have shown neuroprotective effects in some studies. In Alzheimer's disease, P2X3 receptors may interact with amyloid-beta pathology and contribute to synaptic dysfunction. ATP signaling is generally increased in the aging brain and in neurodegenerative conditions, which could lead to abnormal P2X3 receptor activation. However, the specific roles of P2X3 receptors in neurodegeneration require further investigation to determine whether targeting these receptors could provide therapeutic benefits. [@p lu][@p smith]
P2X3 receptor antagonists represent a novel approach to pain management that differs from traditional analgesics. By targeting a receptor expressed specifically in pain-sensing neurons, P2X3 antagonists may provide analgesia without the sedation, addiction potential, and respiratory depression associated with opioids. Clinical trials of P2X3 antagonists in chronic pain conditions have shown mixed results, with some trials demonstrating efficacy in osteoarthritis pain and others failing to meet endpoints. The variable results may reflect differences in patient selection, trial design, or the specific compounds tested. Continued development of more selective and brain-penetrant P2X3 antagonists may improve clinical outcomes. [@p bjorn][@p wu]
Given the role of P2X3 receptors in the trigeminovascular system, these receptors represent potential targets for migraine treatment. P2X3 antagonists have shown efficacy in preclinical models of migraine, and the trigeminal ganglion location makes these receptors accessible to systemically administered drugs. Migraine is a highly prevalent condition with significant unmet therapeutic needs, particularly for patients who do not respond to existing therapies. If P2X3 antagonists prove effective in migraine, they would represent a novel mechanism of action compared to current treatments including triptans, CGRP antagonists, and gepants. [@p martinez]
The efficacy of gefapixant in chronic cough validates P2X3 receptors as therapeutic targets for sensory disorders affecting the respiratory and other organ systems. Chronic cough affects millions of patients and is often refractory to existing treatments. P2X3 antagonists may also be useful for treating overactive bladder, irritable bowel syndrome, and other conditions characterized by visceral hypersensitivity. These applications leverage the role of P2X3 receptors in detecting ATP release from visceral organs and initiating sensory signals that reach consciousness. The successful translation of P2X3 antagonists from preclinical models to clinical practice provides proof-of-concept for targeting purinergic receptors in human disease. [@p xu][@p li]
Despite significant progress, several challenges remain in understanding and targeting P2X3 receptors. Key research priorities include: (1) determining the full repertoire of P2X3 receptor functions in different neuronal and non-neuronal cell types; (2) understanding how P2X3 receptor signaling interacts with other pain-related pathways; (3) developing P2X3 antagonists with optimal pharmacokinetic properties and reduced side effects; (4) identifying biomarkers that predict response to P2X3-targeted therapies; (5) exploring the potential of P2X3 modulation in neurodegenerative diseases; and (6) investigating the therapeutic potential of heteromeric P2X2/3 receptors. The successful development of gefapixant for chronic cough provides a template for advancing other P2X3-targeted therapies, though the complexity of P2X3 receptor biology suggests that continued research is needed to realize the full therapeutic potential of this target.
The following diagram shows the key molecular relationships involving ATP P2X3 Receptor Neurons discovered through SciDEX knowledge graph analysis: